Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety Study of DCCR in Prader-Willi Syndrome
NCT05701774Phase 3Completed
- Sponsor
- Soleno Therapeutics
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of diazoxide choline extended-release in Prader-Willi syndrome (PWS), sponsored by Soleno Therapeutics. Started Jan 2023; status: completed.
02
Drugs
diazoxide choline extended-release
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT05701774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701774.